A practical review on carfilzomib in multiple myeloma

Eli Muchtar, Morie Gertz, Hila Magen

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.

Original languageEnglish (US)
Pages (from-to)564-577
Number of pages14
JournalEuropean Journal of Haematology
Volume96
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Multiple Myeloma
Proteasome Inhibitors
United States Food and Drug Administration
Pharmaceutical Preparations
Appointments and Schedules
Clinical Trials
Safety
carfilzomib

Keywords

  • Carfilzomib
  • Combination regimen
  • Induction
  • Multiple myeloma
  • Proteasome inhibitors
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

A practical review on carfilzomib in multiple myeloma. / Muchtar, Eli; Gertz, Morie; Magen, Hila.

In: European Journal of Haematology, Vol. 96, No. 6, 01.06.2016, p. 564-577.

Research output: Contribution to journalReview article

Muchtar, Eli ; Gertz, Morie ; Magen, Hila. / A practical review on carfilzomib in multiple myeloma. In: European Journal of Haematology. 2016 ; Vol. 96, No. 6. pp. 564-577.
@article{a31b8d25edd74fb885e1663845eb990d,
title = "A practical review on carfilzomib in multiple myeloma",
abstract = "Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.",
keywords = "Carfilzomib, Combination regimen, Induction, Multiple myeloma, Proteasome inhibitors, Relapse",
author = "Eli Muchtar and Morie Gertz and Hila Magen",
year = "2016",
month = "6",
day = "1",
doi = "10.1111/ejh.12749",
language = "English (US)",
volume = "96",
pages = "564--577",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - A practical review on carfilzomib in multiple myeloma

AU - Muchtar, Eli

AU - Gertz, Morie

AU - Magen, Hila

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.

AB - Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.

KW - Carfilzomib

KW - Combination regimen

KW - Induction

KW - Multiple myeloma

KW - Proteasome inhibitors

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84960153174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960153174&partnerID=8YFLogxK

U2 - 10.1111/ejh.12749

DO - 10.1111/ejh.12749

M3 - Review article

VL - 96

SP - 564

EP - 577

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 6

ER -